The efficacy of Aerie Pharmaceuticals Inc.'s glaucoma treatment netarsudil may be limited to patients with low intraocular pressure, but the company does not expect that to be reflected in the indication.
Aerie is seeking US approval for once-daily netarsudil, proposed trade name Rhopressa, approved for reduction of elevated intraocular pressure (IOP)...





